Siga Technologies Inc. (SIGA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Siga Technologies Inc. (SIGA) Surpasses Market Returns: Some Facts Worth Knowing
In the most recent trading session, Siga Technologies Inc. (SIGA) closed at $6.47, indicating a +1.25% shift from the previous trading day.
Siga Technologies Inc. (SIGA) Stock Dips While Market Gains: Key Facts
Siga Technologies Inc. (SIGA) closed the most recent trading day at $6.23, moving -0.24% from the previous trading session.
Siga Technologies Inc. (SIGA) Advances But Underperforms Market: Key Facts
The latest trading day saw Siga Technologies Inc. (SIGA) settling at $6.35, representing a +0.32% change from its previous close.
Are Investors Undervaluing Siga Technologies (SIGA) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year?
Here is how Siga Technologies Inc. (SIGA) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.
Should Value Investors Buy Siga Technologies (SIGA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Siga Technologies (SIGA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Siga Technologies (SIGA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook
SIGA Technologies, Inc.'s reliance on TPOXX, coupled with mixed clinical trial results, and the need to renew the contract with the U.S. in 2025, shed doubts about Siga's long-term outlook. Emergent BioSolutions Inc.'s diversified product portfolio and turnaround strategy under new CEO Joseph Papa provides an optimistic long-term outlook. Siga's financial stability is threatened by potential policy changes driven by the new U.S. government and TPOXX's uncertain efficacy against mpox.
SIGA Technologies: Expansion Into mAbs Is Smart, But Eggs Remain In One Basket
SIGA Technologies' stock has declined 37% since my "speculative buy" recommendation in August, driven by a muted response to the mpox outbreak. The initial recommendation was based on the WHO's mpox emergency declaration and potential increased demand for SIGA's lead asset, tecovirimat. The mpox outbreak has waned, and global authorities' response has been less aggressive, leading to lower-than-expected demand for tecovirimat.
Are Investors Undervaluing Siga Technologies (SIGA) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
SIGA Technologies, Inc. (SIGA) Q3 2024 Earnings Call Transcript
SIGA Technologies, Inc. (NASDAQ:SIGA ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Diem Nguyen - CEO Dan Luckshire - CFO Conference Call Participants Jyoti Prakash - Edison Group Operator Good afternoon, ladies and gentlemen, and welcome to the SIGA Technologies Third Quarter 2024 Earnings Call. At this time, all lines are in a listen-only mode.
SIGA Technologies, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SIGA
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.
